Arcadia Biosciences Announces Change of Independent Auditor: Key Details for Investors

Arcadia Biosciences, Inc. (NASDAQ: RKDA) has filed an 8-K with the SEC announcing a significant change in its independent registered public accounting firm. This move could have implications for investors, particularly given the context of the company’s recent financial disclosures and internal control weaknesses.

Key Points from the SEC Filing

• Dismissal of Deloitte & Touche LLP: On March 30, 2026, Arcadia Biosciences’ Audit Committee dismissed Deloitte & Touche LLP as the company’s independent auditor.
• Auditor’s Report Findings: Deloitte’s audit reports for fiscal years ended December 31, 2025 and December 31, 2024 did not contain adverse opinions or disclaimers. However, they did include an explanatory paragraph regarding Arcadia’s ability to continue as a going concern due to accumulated deficits, recurring net losses, net cash used in operations, and insufficient resources to meet anticipated cash requirements. This is highly price sensitive as it signals financial distress.
• No Disagreements, But Material Weaknesses Identified: There were no disagreements between Arcadia and Deloitte on accounting principles or auditing scope. However, Arcadia identified material weaknesses in internal controls over financial reporting, specifically:
  • Insufficient segregation of duties in the financial statement close process
  • Insufficient information system controls, including access and change management
  • Reduction in employee headcount has led to insufficient personnel to maintain effective controls

  These weaknesses were disclosed in the company’s 2025 Form 10-K.

• Engagement of New Auditor: The Audit Committee approved the engagement of Ramirez Jimenez International CPAs (RJI) as the new independent auditor. RJI will begin its engagement with the review of Q1 2026 financials and the audit of the full-year 2026 statements.
• No Prior Consultations with RJI: The company did not consult RJI regarding any accounting principles, potential audit opinions, or reportable events before their engagement.
• Deloitte’s Confirmation: Deloitte provided a letter to the SEC confirming its agreement with the company’s statements regarding its dismissal and confirming no basis to agree or disagree with the engagement of RJI.

Implications for Shareholders and Potential Share Price Impact

• Going Concern Warning: The explicit mention by Deloitte about Arcadia’s “ability to continue as a going concern” is a major red flag for investors. This signals that unless there are material changes in the company’s financial situation, there is a risk of insolvency or the need for additional capital, which could impact share value.
• Material Weaknesses in Internal Controls: The ongoing material weaknesses in financial reporting and information systems may affect the reliability of Arcadia’s financial statements. This increases risk and may lead to further scrutiny from regulators, potential restatements, or difficulty in raising capital.
• Change in Auditor: Auditor changes often attract investor attention, especially when they follow periods of financial difficulty or internal control concerns. The lack of prior consultations with the new auditor (RJI) may indicate a clean break, but also raises questions for investors about the quality and reliability of future audits.
• Leadership Confirmation: The 8-K was signed by Thomas J. Schaefer, Chief Executive Officer, confirming the seriousness of the disclosure.

Other Noteworthy Details

• Arcadia’s Common Shares (RKDA) remain listed on Nasdaq.
• Company is not an emerging growth company.
• There were no reportable disagreements or events outside the material weaknesses disclosed.

Conclusion

The change of auditor, coupled with explicit going concern warnings and persistent material weaknesses in internal controls, is highly relevant for shareholders. These issues may negatively impact investor confidence and share price. Investors should closely monitor subsequent financial disclosures, auditor reports, and any actions taken by management to address the identified weaknesses and financial risks.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a professional advisor before making any investment decisions regarding Arcadia Biosciences, Inc.

View Arcadia Biosciences, Inc. Historical chart here